The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
Nearly 200 participants from 50 Unani Academia and Council participated
The company has seamlessly integrated the business acquired from Yash Pharma into Jagsonpal and are now confident of aligning the margins of the acquired business with that of Jagsonpal ahead of schedule
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Expect the international business including CDMO business to pick-up in the second half of the financial year
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
To co-develop and co-commercialize MK-6070, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager, worldwide except for Japan where Merck retains exclusive rights
Observes no adverse impact of non-nutritive sweetener (NNS) - sucralose on glycemic markers
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
Narayana Hrudayalaya has reported total income of Rs. 1364.44 crores during the period ended June 30, 2024
Being the first approved applicant, Lupin is eligible for 180 days of CGT exclusivity
Revolutionary technology will further boost OneSource’s scientific services offerings
Vijaya Diagnostic Centre has reported total income of Rs. 159.78 crores during the quarter ended June 30, 2024
Indraprastha Medical Corporation has reported total income of Rs. 352.98 crores during the quarter ended June 30, 2024
Cupid Ltd has reported total income of Rs. 44.02 crores during the quarter ended June 30, 2024
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Divis Laboratories has reported total income of Rs. 2,197 crores during the period ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated
